Related Experiment Video

Updated: Oct 2, 2026

In Vitro Assays to Evaluate the Migration, Invasion, and Proliferation of Immortalized Human First-trimester Trophoblast Cell Lines
09:57

In Vitro Assays to Evaluate the Migration, Invasion, and Proliferation of Immortalized Human First-trimester Trophoblast Cell Lines

Published on: March 5, 2019

Effects of troglitazone on the growth and differentiation of hematopoietic cell lines

S Fujimura1, J Suzumiya, K Nakamura

  • 1Department of Laboratory Medicine, Fukuoka University School of Medicine, Jonan-ku, Fukuoka 841-0180, Japan.

International Journal of Oncology
|November 24, 1998
PubMed

Insights

Troglitazone, an antidiabetic drug, halts G1 phase in hematopoietic cells and promotes monocyte differentiation. Higher concentrations also induce apoptosis, revealing its potential in cell cycle regulation and cancer research.

Area of Science:

  • Pharmacology
  • Cell Biology
  • Molecular Biology

Background:

  • Troglitazone (Tro) is a thiazolidinedione class antidiabetic agent.
  • It acts as a specific ligand for PPARgamma, a nuclear receptor regulating cell growth and differentiation.
  • PPARgamma plays a key role in transcriptional regulation of cellular processes.

Purpose of the Study:

  • To investigate the effects of Troglitazone on HL-60 and other hematopoietic cell lines.
  • To determine Troglitazone's impact on cell cycle progression and differentiation.
  • To assess Troglitazone's potential to induce apoptosis in hematopoietic cells.

Main Methods:

  • Treatment of HL-60 and various hematopoietic cell lines with Troglitazone.
  • Cell cycle analysis to detect G1 phase arrest.
  • Morphological and phenotypic analysis to assess differentiation into monocytes.
  • Apoptosis assays at higher Troglitazone concentrations.

Main Results:

  • Troglitazone induced G1 phase arrest in all examined hematopoietic cell lines.
  • HL-60 cells exhibited differentiation into monocytes.
  • Monocytic lineage differentiation was observed in myelogenous, promonocytic, and erythroleukemia cell lines.
  • Apoptosis was induced by Troglitazone at higher concentrations.

Conclusions:

  • Troglitazone effectively inhibits cell cycle progression in hematopoietic cells.
  • Troglitazone promotes differentiation towards the monocytic lineage across various hematopoietic cell types.
  • Troglitazone exhibits dose-dependent effects, inducing apoptosis at higher concentrations.

More Related Videos

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

Related Concept Videos

Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...